Immune Thrombocytopenic Purpura Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

Immune Thrombocytopenic Purpura Overview

Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets. The disease is chronic in adults, but it is usually acute and self-limited in children. Children may develop ITP after a viral infection and usually recover fully without treatment. In adults, the disorder is often long term. The Immune Thrombocytopenic Purpura diagnosis is made by physical examination, medical history, and blood test to count the platelets.

“Immune Thrombocytopenic Purpura Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Immune Thrombocytopenic Purpura Market. 

The Immune Thrombocytopenic Purpura Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Immune Thrombocytopenic Purpura Pipeline Report:

• Companies across the globe are diligently working toward developing novel Immune Thrombocytopenic Purpura treatment therapies with a considerable amount of success over the years. Immune Thrombocytopenic Purpura Key players such as – Cour Pharmaceutical, Pfizer, Takeda, Genosco, InnoCare Pharma, Principia Biopharma, Sanofi, UCB Biopharma, argenx, and others, are developing therapies for the Immune Thrombocytopenic Purpura treatment 

• Immune Thrombocytopenic Purpura Emerging therapies such as – CNP-ITP, PF-06755347, Mezagitamab, Cevidoplenib , Orelabrutinib, Rilzabrutinib, Rozanolixizumab, Efgartigimod, and others are expected to have a significant impact on the Immune Thrombocytopenic Purpura market in the coming years.
• In April 2018, the United States FDA granted orphan drug designation to rozanolixizumab, for the treatment of idiopathic thrombocytopenic purpura. In January 2019, orphan designation (EU/3/18/2131) was granted by the European Commission to UCB Biopharma S.P.R.L., Belgium, for rozanolixizumab for the treatment of immune thrombocytopenia   
• In January 2020, UCB Biopharma initiated a Phase III multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP). The trial is estimated to get completed by August 2022 with 90 participants
• In September 2020, UCB announced positive results from a Phase II study (TP0001; NCT02718716) of rozanolixizumab. The results were published in the September online issue of Blood Advances. 

Immune Thrombocytopenic Purpura Pipeline Therapeutics Assessment 

• Immune Thrombocytopenic Purpura Assessment by Product Type
• Immune Thrombocytopenic Purpura By Stage and Product Type
• Immune Thrombocytopenic Purpura Assessment by Route of Administration
• Immune Thrombocytopenic Purpura By Stage and Route of Administration
• Immune Thrombocytopenic Purpura Assessment by Molecule Type
• Immune Thrombocytopenic Purpura by Stage and Molecule Type 

DelveInsight’s Immune Thrombocytopenic Purpura Report covers around 5+ products under different phases of clinical development like 

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Immune Thrombocytopenic Purpura Drugs Under Different Phases of Clinical Development Include:

• CNP-ITP: Cour Pharmaceutical
• PF-06755347: Pfizer
• Mezagitamab: Takeda
• Cevidoplenib: Genosco
• Orelabrutinib: InnoCare Pharma
• Rilzabrutinib: Principia Biopharma (Sanofi
• Rozanolixizumab: UCB Biopharma
• Efgartigimod: argenx 

Get a Free Sample PDF Report to know more about Immune Thrombocytopenic Purpura Pipeline Assessment

Immune Thrombocytopenic Purpura Pipeline Analysis:

The Immune Thrombocytopenic Purpura pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Immune Thrombocytopenic Purpura treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Immune Thrombocytopenic Purpura Treatment.
• Immune Thrombocytopenic Purpura key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Immune Thrombocytopenic Purpura Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Immune Thrombocytopenic Purpura market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Immune Thrombocytopenic Purpura product details are provided in the report. Download the Immune Thrombocytopenic Purpura pipeline report to learn more about the emerging Immune Thrombocytopenic Purpura therapies

Scope of Immune Thrombocytopenic Purpura Pipeline Drug Insight    

• Coverage: Global
• Key Immune Thrombocytopenic Purpura Companies: Cour Pharmaceutical, Pfizer, Takeda, Genosco, InnoCare Pharma, Principia Biopharma, Sanofi, UCB Biopharma, argenx,, and others
• Key Immune Thrombocytopenic Purpura Therapies: CNP-ITP, PF-06755347, Mezagitamab, Cevidoplenib , Orelabrutinib, Rilzabrutinib, Rozanolixizumab, Efgartigimod, and others
• Immune Thrombocytopenic Purpura Therapeutic Assessment: Immune Thrombocytopenic Purpura current marketed and Immune Thrombocytopenic Purpura emerging therapies
• Immune Thrombocytopenic Purpura Market Dynamics:  Immune Thrombocytopenic Purpura market drivers and Immune Thrombocytopenic Purpura market barriers 

Request for Sample PDF Report for Immune Thrombocytopenic Purpura Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Immune Thrombocytopenic Purpura drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/